Compare IDEXX Laboratories, Inc. (IDXX) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Microsoft — how do they compare? IDEXX Laboratories, Inc. trades at $553.76 (market cap $44.48B), while Microsoft trades at $398.61 (market cap $2.99T). The key difference: Microsoft is far larger — about 67.2× IDEXX Laboratories, Inc.'s market cap, and Microsoft pays a 0.9% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MSFT | |
|---|---|---|
Market Cap | $44.48B | $2.99T |
Sector | Health | Technology |
52-Week High | $766.68 | $542.07 |
52-Week Low | $520.87 | $352.83 |
Enterprise Value | $45.38B | $2.97T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Microsoft (MSFT) trades at $399.48, up 1.44% today, with strong technical momentum as the stock approaches resistance at $407. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.27 versus $4.06, continuing a trend of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $281.72 billion and net income of $101.83 billion, supported by strong cash flow generation of $136.16 billion from operations.
Microsoft's outlook remains positive with 80% analyst buy ratings and a $546.70 consensus price target representing 37% upside potential. Key opportunities include AI leadership through Azure and Copilot, while risks include elevated capital expenditures and competitive pressures in cloud computing. The stock's current valuation at 23.96 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
